Biotech Co. Hid Cancer Drug Concerns, Investors Say
A cancer therapy developer led shareholders to believe testing for its new leukemia treatment drug was going smoothly despite the U.S. Food and Drug Administration's concerns that the drug causes liver...To view the full article, register now.
Already a subscriber? Click here to view full article